MedTrace Logo

Safety and Efficacy of Nitrogen Mustard in Treatment of Mycosis Fungoides

NCT00168064 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260

Last updated 2012-10-31

Study results available
· View outcomes & findings →

Summary

This study will evaluate the efficacy, tolerability and safety of the topical application of mechlorethamine (MCH) formulations in patients with stage I or IIA mycosis fungoides (MF).

Conditions

  • Mycosis Fungoides

Interventions

DRUG

mechlorethamine-MCH (nitrogen mustard)

All affected areas (lesions) are to be treated once daily for twelve months with mechlorethamine-MCH (nitrogen mustard) 0.02% PG or NM 0.02% AP ointment

Sponsors & Collaborators

  • Yaupon Therapeutics

    lead INDUSTRY

Principal Investigators

  • Stuart Lessin, M.D. · Fox Chase Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2010-08-31
Completion
2011-08-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00168064 on ClinicalTrials.gov